Abstract
A feruloyl esterase (FAE) gene was isolated from a rumen microbial metagenome, cloned into E. coli, and expressed in active form. The enzyme (RuFae4) was classified as a Type D feruloyl esterase based on its action on synthetic substrates and ability to release diferulates. The RuFae4 alone released ferulic acid (FA) and diferulic acid (diFA) from wheat insoluble arabinoxylan (WIA) and other natural substrates. The diFA released was confirmed by mass spectrometry. A maximum of 205±5.7 µg FA and 0.84±0.1 µg diFA were released (37°C, pH 6.5, 2 hr) when a saturating amount of RuFae4 (23 nmole for 100 mg WIA) was used. These yields represent 48.3% of FA, and 6.6% of diFAs present in the WIA substrate. Addition of GH10 endoxylanase (EX) to RuFae4 both at 1 nmole concentrations increased the release of FA and diFAs by 17 and 10 fold, respectively. Addition of GH11 EX resulted in smaller increase in the amount of both FA and diFAs. Applying additive amount of the two enzymes did not lead to additive increase in the product yields, suggesting that it was primarily the GH10 enzyme contributing synergism to FA/diFA release in mixed reactions.
Keywords: Arabinoxylan, ferulic acid, ferulic acid esterase, feruloyl esterase, metagenomics.
Graphical Abstract
Protein & Peptide Letters
Title:Cloning of a Novel Feruloyl Esterase from Rumen Microbial Metagenome for Substantial Yield of Mono- and Diferulic Acids from Natural Substrates
Volume: 22 Issue: 8
Author(s): Dominic W. S. Wong, Gary Takeoka, Victor J. Chan, Hans Liao and Mario T. Murakami
Affiliation:
Keywords: Arabinoxylan, ferulic acid, ferulic acid esterase, feruloyl esterase, metagenomics.
Abstract: A feruloyl esterase (FAE) gene was isolated from a rumen microbial metagenome, cloned into E. coli, and expressed in active form. The enzyme (RuFae4) was classified as a Type D feruloyl esterase based on its action on synthetic substrates and ability to release diferulates. The RuFae4 alone released ferulic acid (FA) and diferulic acid (diFA) from wheat insoluble arabinoxylan (WIA) and other natural substrates. The diFA released was confirmed by mass spectrometry. A maximum of 205±5.7 µg FA and 0.84±0.1 µg diFA were released (37°C, pH 6.5, 2 hr) when a saturating amount of RuFae4 (23 nmole for 100 mg WIA) was used. These yields represent 48.3% of FA, and 6.6% of diFAs present in the WIA substrate. Addition of GH10 endoxylanase (EX) to RuFae4 both at 1 nmole concentrations increased the release of FA and diFAs by 17 and 10 fold, respectively. Addition of GH11 EX resulted in smaller increase in the amount of both FA and diFAs. Applying additive amount of the two enzymes did not lead to additive increase in the product yields, suggesting that it was primarily the GH10 enzyme contributing synergism to FA/diFA release in mixed reactions.
Export Options
About this article
Cite this article as:
W. S. Wong Dominic, Takeoka Gary, J. Chan Victor, Liao Hans and T. Murakami Mario, Cloning of a Novel Feruloyl Esterase from Rumen Microbial Metagenome for Substantial Yield of Mono- and Diferulic Acids from Natural Substrates, Protein & Peptide Letters 2015; 22 (8) . https://dx.doi.org/10.2174/0929866522666150428114053
DOI https://dx.doi.org/10.2174/0929866522666150428114053 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histamine H3 Receptor Function and Ligands: Recent Developments
Mini-Reviews in Medicinal Chemistry CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Long-Chain Omega-3 Fatty Acid Deficiency in Mood Disorders: Rationale for Treatment and Prevention
Current Drug Discovery Technologies The Progress of Epilepsy after Stroke
Current Neuropharmacology Editorial [ Hot Topic:Physical Activity, Exercise and Aging (Guest Editors: Yolanda Escalante and Jose M. Saavedra )]
Current Aging Science Management of Impulse Control Disorders with Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer’s Disease Therapy: Advances in Chemical and Biological Research
Current Medicinal Chemistry The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Current Diabetes Reviews Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Dual Inhibitors of β-Amyloid Aggregation and Acetylcholinesterase as Multi-Target Anti-Alzheimer Drug Candidates
Current Topics in Medicinal Chemistry Statins in Bacteremia, Sepsis and Pneumonia: Have We Found the Holy Grail?
Recent Patents on Inflammation & Allergy Drug Discovery Investigation of the CYP2C9 Induction Profile in Human Hepatocytes by Combining Experimental and Modelling Approaches
Current Drug Metabolism In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Current Medicinal Chemistry Advances in Metabonomics on Infectious Diseases
Current Metabolomics Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews Lipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Advances in High-Field Magnetic Resonance Spectroscopy in Alzheimer’s Disease
Current Alzheimer Research Aligned Expression of IFI16 and STING Genes in RRMS Patients’ Blood
Endocrine, Metabolic & Immune Disorders - Drug Targets